SalPyr-1

SalPyr-1 is an experimental **small-molecule salicylanilide derivative**, described in the literature as a **salicylanilide 5-chloropyrazinoate** evaluated as an anticancer compound in preclinical research. In the cited study, it was tested in **U87 human glioblastoma** cells and showed reduced cell viability; the reported cell-death phenotype was associated with **autophagy activation**, based on light chain 3 protein processing. There is no evidence from the provided source that SalPyr-1 is an approved medicine, clinically developed asset, branded product, or company-sponsored pipeline program; it appears to be a **research compound** from an academic medicinal chemistry program rather than a clinically established drug.

Other names

salicylanilide 5-chloropyrazinoatesalicylanilide5-chloropyrazinoatesalicylanilide-5-chloropyrazinoate